Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants With Hereditary Angioedema - ORBIT-EXPANSE

NCT07204938 is registered in ClinicalTrials.gov with Astria Therapeutics, Inc. as lead sponsor.

NCT NCT07204938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07204938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants With Hereditary Angioedema - ORBIT-EXPANSE
Lead sponsor
Astria Therapeutics, Inc.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
October 1, 2025
Completion date
December 31, 2031
Enrollment
145 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)